iBio Q3 net loss $2.6M; cash raised to $17.9M via PIPE; enters AstralBio collaboration

iBio, Inc.

2024-Q3 EPS reported -$7.62 revenue$50,000

Net loss from continuing ops: $2.6M ($0.71/share) vs $6.3M ($9.53/share) YoY; no revenue.
R&D expenses down 66%, G&A down 23% YoY under cash preservation strategy.
Cash and equivalents $17.9M after $15M PIPE closed in April, up from $6.4M at March 31.
Partnered with AstralBio to develop 4 antibody targets for obesity/cardiometabolic diseases.
Sold early-stage PD-1 asset to Otsuka for $1M upfront and up to $52.5M in contingent payments.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

iBio, Inc. reported financial results for third quarter ended March 31, 2024.

Period: third quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 13, 2024, iBio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

iBio, Inc. filing history →

Source: SEC EDGAR

accession 0001420720-24-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.